Goodman Joanne, Agoram Balaji
Medimmune, Cambridge, CB21 6GH, UK.
Bioanalysis. 2013 Dec;5(23):2919-31. doi: 10.4155/bio.13.262.
Quantification of soluble biomarkers is critical for assessing target engagement in both preclinical and clinical settings. Since the advent of the commonly used ELISA, there has been an array of immunoassay platforms to achieve this goal, and many researchers will have a favorite. This review will compare and contrast immunoassay technologies used by many pharmaceutical and CRO groups and highlight emerging assay platforms that may deliver more sensitive assays. Several case studies will be used throughout as the changing immunoassay landscape is discussed.
可溶性生物标志物的定量对于评估临床前和临床环境中的靶点结合情况至关重要。自从常用的酶联免疫吸附测定(ELISA)问世以来,已经出现了一系列免疫测定平台来实现这一目标,许多研究人员都有自己偏爱的平台。本综述将比较和对比众多制药和合同研究组织(CRO)集团所使用的免疫测定技术,并重点介绍可能提供更灵敏测定的新兴测定平台。在讨论不断变化的免疫测定格局时,将贯穿使用几个案例研究。